Results from studies using PDL1 inhibitors
Today, at the World Conference on Lung Cancer 2016 (Mesothelioma Track), several investigators presented data for their immunotherapy studies. The first three presentations focused on PDL1 inhibitors.
Dr. Paul Baas began the session by presenting data from his Phase II study of nivolumab, an immunotherapy agent. Though his study showed no complete response in the 34 patients in the trial, he did report a disease control rate of 50%. Responses were seen in all groups of patients regardless of PDL1 expression.
The next presenter was Dr. Hedy Kindler of the University of Chicago, who presented an interim analysis of her Phase II trial of pembrolizumab, another immunotherapy agent very similar to nivolumab. Dr. Kindler’s data looked at 34 patients. Dr. Kindler saw a disease control rate of 80%.
Dr. Evan Alley from the University of Pennsylvania followed by presenting on long-term overall survival for mesothelioma patients on pembrolizumab enrolled in the KEYNOTE-028 study. His data, based on 25 patients, showed a disease control rate of 72%.
“We really look forward to learning more about these drugs as these data continues to mature,” said Mary Hesdorffer, nurse practitioner and executive director of the Mesothelioma Applied Research Foundation.
It should be noted that the above-reported results should not be compared between them as they used different study designs. Please contact Mary Hesdorffer at [email protected] to obtain more information.
You can learn more about PD-L1 inhibitors by reading these articles that we have previously written.
